<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03339713</url>
  </required_header>
  <id_info>
    <org_study_id>CR108403</org_study_id>
    <secondary_id>VAC18193RSV2003</secondary_id>
    <nct_id>NCT03339713</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase 2a Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and Ad26.RSV.preF, With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Janssen Vaccines &amp; Prevention B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Janssen Vaccines &amp; Prevention B.V.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the non-inferiority of the concomitant
      administration of an adenovirus serotype 26- based vaccine encoding for the respiratory
      syncytial virus pre-fusion F protein (Ad26.RSV.preF) and seasonal influenza vaccine versus
      the administration of seasonal influenza vaccine alone in terms of humoral immune response
      expressed by the geometric mean titers (GMTs) of hemagglutination inhibition (HI) antibody
      titers against all four influenza vaccine strains 28 days after the administration of
      influenza vaccine, and to assess the safety and tolerability of a single dose of 1*10^11
      viral particles (vp) of Ad26.RSV.preF, administered intramuscularly to participants aged
      greater than or equal to 60 years separately or concomitantly with seasonal influenza
      vaccine.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">December 7, 2017</start_date>
  <completion_date type="Anticipated">July 13, 2018</completion_date>
  <primary_completion_date type="Anticipated">March 29, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hemagglutination Inhibition (HI) Antibody Titers as Measured by Hemagglutination Inhibition Assay (HAI) Against Each of the Four Vaccine Influenza Strains</measure>
    <time_frame>Day 28</time_frame>
    <description>Humoral immune responses expressed by the geometric mean titers (GMTs) of HI antibody titers against each of four influenza vaccine strains.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Solicited Local and Systemic Adverse Events (AEs) After Vaccination</measure>
    <time_frame>7 days after each vaccination (up to Day 36)</time_frame>
    <description>Following solicited local AEs (erythema, swelling/induration, and pain/tenderness) and solicited systemic AEs (fatigue, headache, myalgia, arthralgia, chills, nausea and fever) will be noted in the participant diary after 7 days of each vaccination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Unsolicited Adverse Events</measure>
    <time_frame>From signing informed consent form until 28 days after each vaccination (up to Day 57)</time_frame>
    <description>Unsolicited AEs are all AEs for which participants are specifically not questioned in the participant diary. An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAEs)</measure>
    <time_frame>From signing ICF to throughout the study (up to 6 months)</time_frame>
    <description>An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Respiratory Syncytial Virus (RSV) A2 Strain Neutralization Antibody Titers</measure>
    <time_frame>Pre-Vaccination on (Days 1 and 28) and at 28 days after the second vaccination (Day 57)</time_frame>
    <description>Analysis of RSV A2 neutralizing titers of the vaccine-induced immune response will be assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RSV Fusion Protein (F-protein) Enzyme-linked Immunosorbent Assay (ELISA)</measure>
    <time_frame>Pre-Vaccination on (Days 1 and 28) and at 28 days after the second vaccination (Day 57)</time_frame>
    <description>Analysis of antibodies binding to RSV F protein in post-fusion and pre-fusion form by ELISA.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Ad26.RSV.preF Plus Fluarix Then Placebo: Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intramuscular injection of 1*10^11 viral particles (vp) of an adenovirus serotype 26- based vaccine encoding for the respiratory syncytial virus pre-fusion F protein (Ad26.RSV.preF) on 1 arm administered at the same time as a commercially available seasonal influenza vaccine (Fluarix) on the other arm at Day 1, and intramuscular injection of placebo on Day 29.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Plus Fluarix Then Ad26.RSV.preF: Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive intramuscular injection of placebo administered at the same time as a commercially available seasonal influenza vaccine (Fluarix) on Day 1, and 1*10^11 vp of Ad26.RSV.preF on Day 29.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Ad26.RSV.preF</intervention_name>
    <description>Ad26.RSV.preF will be administered as intramuscular injection at a dose of 1*10^11 vp.</description>
    <arm_group_label>Ad26.RSV.preF Plus Fluarix Then Placebo: Group 1</arm_group_label>
    <arm_group_label>Placebo Plus Fluarix Then Ad26.RSV.preF: Group 2</arm_group_label>
    <other_name>JNJ-64400141</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Fluarix</intervention_name>
    <description>Fluarix will be administered as intramuscular injection.</description>
    <arm_group_label>Ad26.RSV.preF Plus Fluarix Then Placebo: Group 1</arm_group_label>
    <arm_group_label>Placebo Plus Fluarix Then Ad26.RSV.preF: Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will be administered as intramuscular injection of sterile 0.9 percent (%) saline for injection.</description>
    <arm_group_label>Ad26.RSV.preF Plus Fluarix Then Placebo: Group 1</arm_group_label>
    <arm_group_label>Placebo Plus Fluarix Then Ad26.RSV.preF: Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Each participant must sign an informed consent form (ICF) indicating that he or she
             understands the purpose of and procedures required for the study, is willing to
             participate in the study and attend all scheduled visits, and is willing and able to
             comply with all study procedures and adhere to the prohibitions and restrictions
             specified in this protocol

          -  Before randomization, a woman must be:

               1. Postmenopausal (A postmenopausal state is defined as no menses for 12 months
                  without an alternative medical cause) and

               2. Not intending to conceive by any methods

          -  In the investigator's clinical judgment, participant must be either in good or stable
             health, and not at risk of serious complications from influenza. Participants may have
             underlying illnesses such as hypertension, type 2 diabetes, hyperlipoproteinemia, or
             hypothyroidism, as long as their symptoms/signs are medically controlled. If they are
             on medication for a condition, the medication dose must have been stable for at least
             12 weeks (or only small, clinically non-significant changes have been made in the
             judgement of the Principal Investigator) preceding vaccination and expected to remain
             stable for the duration of the study. Participants will be included on the basis of
             physical examination, medical history, vital signs, and 12-lead electrocardiogram
             (ECG) performed on Day 1

          -  From the time of first vaccination through 3 months after the second dose of study
             vaccine, participant agrees not to donate blood

          -  Participant must be willing to provide verifiable identification, have means to be
             contacted and to contact the investigator during the study

        Exclusion Criteria:

          -  Participant has acute illness (this does not include minor illnesses such as diarrhea)
             or temperature greater than or equal to (&gt;=) 38.0 degree Celsius (ÂºC) within 24 hours
             prior to the first dose of study vaccine; enrollment at a later date is permitted

          -  Participant has a serious chronic disorder, including severe chronic obstructive
             pulmonary disease or clinically significant congestive heart failure, requirement for
             supplemental oxygen, end stage renal disease with or without dialysis, clinically
             unstable cardiac disease, Alzheimer's disease, or has any condition for which, in the
             opinion of the investigator, participation would not be in the best interest of the
             participant (for example, compromise well-being) or that could prevent, limit, or
             confound the protocol-specified assessments

          -  Participant has history of malignancy within 5 years before screening (exceptions are
             squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or
             malignancy, which is considered cured with minimal risk of recurrence)

          -  Participant has had major surgery (per the investigator's judgment), within 4 weeks
             before dosing, or will not have fully recovered from surgery, or has surgery planned
             during the time the participant is expected to participate in the study or within 6
             months after the final dose of study vaccine

          -  Participant has chronic active hepatitis B or hepatitis C infection, documented by
             hepatitis B surface antigen and hepatitis C antibody, respectively
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janssen Vaccines &amp; Prevention B.V. Clinical Trial</last_name>
    <role>Study Director</role>
    <affiliation>Janssen Vaccines &amp; Prevention B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Coastal Carolina Research Center</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://pam.sylogent.com/cr/CR108403</url>
    <description>To learn how to participate in this trial please click here.</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2017</study_first_submitted>
  <study_first_submitted_qc>November 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2017</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

